On September 25, XenoPort entered into a master manufacturing and supply agreement with Patheon Pharmaceuticals pursuant to which Patheon agreed to supply the company with commercial supplies of Horizant (gabapentin enacarbil) Extended-Release Tablets. Patheon is currently qualified by the U.S. Food and Drug Administration to manufacture and supply the Product and has served as a contract manufacturer of the Product for Glaxo Group Limited. Under the supply agreement, the company will provide non-binding rolling forecasts to Patheon of its long-term requirements for the product, and from time-to-time deliver binding firm purchase orders for manufacturing and supply of the product. During the term of the Supply Agreement, Patheon is not permitted to manufacture gabapentin enacarbil (or any product containing gabapentin enacarbil) for any party other than the company, its designee or any authorized licensee of the Company. The Supply Agreement commenced on September 25 and expires on December 31, 2025, and thereafter will automatically renew for one-year periods unless either party provides 18 months prior notice of its desire not to renew.This information is from a regulatory filing.
- Health Care Industry